AbbVie pours $223M into building out its biologics capacity in Singapore

AbbVie, a global biopharmaceutical company, has announced a $223 million investment to expand its biologics manufacturing capacity in Singapore. The expansion will take place at AbbVie's Singapore manufacturing site, which is the company's only manufacturing plant in Asia. The investment will add 24,000 liters of biologics drug-substance capacity to support AbbVie's current products and emerging immunology and oncology therapeutics.

Key aspects of the expansion include:

- The Singapore manufacturing site will grow to more than 500 employees following the expansion.
- Construction will commence later this year, with facilities becoming operational in 2026.
- The expansion will create more than 100 new jobs in manufacturing, quality assurance, supply chain, engineering, and administration roles.
- AbbVie has invested more than $740 million in acquiring, modernizing, and expanding its Singapore facility over the past decade.

This expansion demonstrates AbbVie's commitment to strengthening its global manufacturing capabilities and supporting its growing biologics pipeline. The investment will also enhance Singapore's leading advanced manufacturing ecosystem and create new job opportunities in the biopharmaceutical sector.